https://pharmaphorum.com/news/scotlands-cost-regulator-rejects-vertex-cystic-fibrosis-drugs/?utm_source=pharmaphorum+Daily+Newsletter&utm_campaign=4691e15288-EMAIL_CAMPAIGN_2019_07_25_12_41_COPY_01&utm_medium=email&utm_term=0_a54496134b-4691e15288-431716241
The Scottish Medicines Consortium’s decision came in its monthly round of drug cost-effectiveness decisions, which included a recommendation to fund Akcea’s pricey rare disease drug Tegsedi (inotersen) for adults with hereditary transthyretin amyloidosis (hATTR).
Orkambi (lumacaftor+ivacaftor) and Symkevi (tezacaftor+ivacaftor) were deemed too expensive despite an assessment that included greater involvement from patients and clinicians...
The Scottish Medicines Consortium’s decision came in its monthly round of drug cost-effectiveness decisions, which included a recommendation to fund Akcea’s pricey rare disease drug Tegsedi (inotersen) for adults with hereditary transthyretin amyloidosis (hATTR).
Orkambi (lumacaftor+ivacaftor) and Symkevi (tezacaftor+ivacaftor) were deemed too expensive despite an assessment that included greater involvement from patients and clinicians...